CN1225528C - Supercritical CO2 extraction process for preparing ant oil - Google Patents
Supercritical CO2 extraction process for preparing ant oil Download PDFInfo
- Publication number
- CN1225528C CN1225528C CN 200410015825 CN200410015825A CN1225528C CN 1225528 C CN1225528 C CN 1225528C CN 200410015825 CN200410015825 CN 200410015825 CN 200410015825 A CN200410015825 A CN 200410015825A CN 1225528 C CN1225528 C CN 1225528C
- Authority
- CN
- China
- Prior art keywords
- ant
- extraction
- oil
- supercritical
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000605 extraction Methods 0.000 title claims abstract description 59
- 239000000843 powder Substances 0.000 claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 10
- 241000257303 Hymenoptera Species 0.000 claims abstract description 6
- 241001251068 Formica fusca Species 0.000 claims description 32
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 18
- 239000003925 fat Substances 0.000 claims description 15
- 239000012530 fluid Substances 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 13
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 claims description 12
- 239000006187 pill Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000007901 soft capsule Substances 0.000 claims description 8
- 239000003094 microcapsule Substances 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003292 glue Substances 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 240000005020 Acaciella glauca Species 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- 239000001116 FEMA 4028 Substances 0.000 claims description 3
- 241001420794 Formica rufa Species 0.000 claims description 3
- 241001507629 Formicidae Species 0.000 claims description 3
- 241000500891 Insecta Species 0.000 claims description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 3
- 229960004853 betadex Drugs 0.000 claims description 3
- 230000001351 cycling effect Effects 0.000 claims description 3
- 235000003499 redwood Nutrition 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 13
- 239000002253 acid Substances 0.000 abstract description 12
- 239000003960 organic solvent Substances 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract description 3
- 125000003118 aryl group Chemical group 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 3
- 239000011573 trace mineral Substances 0.000 abstract description 3
- 235000013619 trace mineral Nutrition 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 238000003912 environmental pollution Methods 0.000 abstract description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000002052 anaphylactic effect Effects 0.000 abstract 1
- 239000003205 fragrance Substances 0.000 abstract 1
- 235000013402 health food Nutrition 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000013557 residual solvent Substances 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 37
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- -1 8-hexyl 8-hexyl pentadecane Heptadecane Chemical compound 0.000 description 15
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 10
- 235000013305 food Nutrition 0.000 description 9
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 8
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 8
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 239000005642 Oleic acid Substances 0.000 description 8
- 150000001336 alkenes Chemical class 0.000 description 8
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- NDJKXXJCMXVBJW-UHFFFAOYSA-N heptadecane Chemical compound CCCCCCCCCCCCCCCCC NDJKXXJCMXVBJW-UHFFFAOYSA-N 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 229910000831 Steel Inorganic materials 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- XIRNKXNNONJFQO-UHFFFAOYSA-N ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC XIRNKXNNONJFQO-UHFFFAOYSA-N 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000010959 steel Substances 0.000 description 6
- 239000000341 volatile oil Substances 0.000 description 6
- WRXZZORBTUGCDV-UHFFFAOYSA-N 13,17-dimethylhentriacontane Chemical compound CCCCCCCCCCCCCCC(C)CCCC(C)CCCCCCCCCCCC WRXZZORBTUGCDV-UHFFFAOYSA-N 0.000 description 5
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 5
- 241001660172 Polyrhachis Species 0.000 description 5
- 229960004232 linoleic acid Drugs 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- KZJWDPNRJALLNS-FBZNIEFRSA-N clionasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-FBZNIEFRSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000002398 materia medica Substances 0.000 description 4
- NHLUYCJZUXOUBX-UHFFFAOYSA-N nonadec-1-ene Chemical compound CCCCCCCCCCCCCCCCCC=C NHLUYCJZUXOUBX-UHFFFAOYSA-N 0.000 description 4
- YCOZIPAWZNQLMR-UHFFFAOYSA-N pentadecane Chemical compound CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- RLHIRZFWJBOHHD-UHFFFAOYSA-N 3,5-cholestadiene Natural products C1C=C2C=CCCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 RLHIRZFWJBOHHD-UHFFFAOYSA-N 0.000 description 3
- RLHIRZFWJBOHHD-HKQCOZBKSA-N Cholesta-3,5-diene Chemical compound C1C=C2C=CCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 RLHIRZFWJBOHHD-HKQCOZBKSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- RZJRJXONCZWCBN-UHFFFAOYSA-N alpha-octadecene Natural products CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 3
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 229940067592 ethyl palmitate Drugs 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 3
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 3
- BLCUZCCTSBVFSV-LAPDZXRHSA-N (e)-pentatriacont-17-ene Chemical compound CCCCCCCCCCCCCCCCC\C=C\CCCCCCCCCCCCCCCC BLCUZCCTSBVFSV-LAPDZXRHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- SPURMHFLEKVAAS-UHFFFAOYSA-N 1-docosene Chemical compound CCCCCCCCCCCCCCCCCCCCC=C SPURMHFLEKVAAS-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 240000008415 Lactuca sativa Species 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000005470 impregnation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- QJAOYSPHSNGHNC-UHFFFAOYSA-N octadecane-1-thiol Chemical compound CCCCCCCCCCCCCCCCCCS QJAOYSPHSNGHNC-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical class CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 235000012045 salad Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- REZQBEBOWJAQKS-UHFFFAOYSA-N triacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO REZQBEBOWJAQKS-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- ADHNUPOJJCKWRT-JLXBFWJWSA-N (2e,4e)-octadeca-2,4-dienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C(O)=O ADHNUPOJJCKWRT-JLXBFWJWSA-N 0.000 description 1
- ADHNUPOJJCKWRT-SENDIRFWSA-N (2z)-octadeca-2,4-dienoic acid Chemical compound CCCCCCCCCCCCCC=C\C=C/C(O)=O ADHNUPOJJCKWRT-SENDIRFWSA-N 0.000 description 1
- PJHOFUXBXJNUAC-KTKRTIGZSA-N (Z)-hexadec-7-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCC(O)=O PJHOFUXBXJNUAC-KTKRTIGZSA-N 0.000 description 1
- LHPVEDYVSCTZAY-LUAWRHEFSA-N (z)-nonadec-5-ene Chemical compound CCCCCCCCCCCCC\C=C/CCCC LHPVEDYVSCTZAY-LUAWRHEFSA-N 0.000 description 1
- QCOWNEUAMDSCFW-UHFFFAOYSA-N 11-methyloctacosane Chemical compound CCCCCCCCCCCCCCCCCC(C)CCCCCCCCCC QCOWNEUAMDSCFW-UHFFFAOYSA-N 0.000 description 1
- VPFCOUMSFTYCMR-UHFFFAOYSA-N 2,2-dimethylheptadecane Chemical compound CCCCCCCCCCCCCCCC(C)(C)C VPFCOUMSFTYCMR-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-UHFFFAOYSA-N 9,12-Octadecadienoic Acid Chemical compound CCCCCC=CCC=CCCCCCCCC(O)=O OYHQOLUKZRVURQ-UHFFFAOYSA-N 0.000 description 1
- HCGHTSMPJQUZCK-UHFFFAOYSA-N 9-heptyloctadecane Chemical compound CCCCCCCCCC(CCCCCCC)CCCCCCCC HCGHTSMPJQUZCK-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241001253206 Andrias Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- PIYVOXCOQMTZEH-KVVVOXFISA-N C(C=CC=CCCCCCCCCCCCCC)(=O)O.C(CCCCCCC\C=C/CCCCCCCC)(=O)O Chemical compound C(C=CC=CCCCCCCCCCCCCC)(=O)O.C(CCCCCCC\C=C/CCCCCCCC)(=O)O PIYVOXCOQMTZEH-KVVVOXFISA-N 0.000 description 1
- BKAXLKWWNXLFBE-UHFFFAOYSA-N C(CCCCCCCCCCCCCCCCCCCCCC)O.C(CCCCCCCCCCCCCCCCCCCCC)O Chemical compound C(CCCCCCCCCCCCCCCCCCCCCC)O.C(CCCCCCCCCCCCCCCCCCCCC)O BKAXLKWWNXLFBE-UHFFFAOYSA-N 0.000 description 1
- CMGMMONGRBKBRP-UHFFFAOYSA-N CCCCCCCCCCCC.C(CCCCCCCCCCCCCCCCC)(=O)O Chemical compound CCCCCCCCCCCC.C(CCCCCCCCCCCCCCCCC)(=O)O CMGMMONGRBKBRP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001660166 Camponotus japonicus Species 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- DBPRUZCKPFOVDV-UHFFFAOYSA-N Clorprenaline hydrochloride Chemical compound O.Cl.CC(C)NCC(O)C1=CC=CC=C1Cl DBPRUZCKPFOVDV-UHFFFAOYSA-N 0.000 description 1
- 241001633942 Dais Species 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241001251094 Formica Species 0.000 description 1
- 241001241064 Formica sanguinea Species 0.000 description 1
- JELGPLUONQGOHF-UHFFFAOYSA-N Hexadec-9-ensaeure-ethylester Natural products CCCCCCC=CCCCCCCCC(=O)OCC JELGPLUONQGOHF-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 1
- 208000019395 Lactation disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001660113 Oecophylla smaragdina Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001660135 Polyrhachis dives Species 0.000 description 1
- 241000802381 Polyrhachis vicina Species 0.000 description 1
- 241001620634 Roger Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010042576 Suppressed lactation Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- JELGPLUONQGOHF-MDZDMXLPSA-N ethyl 9-hexadecenoate Chemical compound CCCCCC\C=C\CCCCCCCC(=O)OCC JELGPLUONQGOHF-MDZDMXLPSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- BIQKRILZMDQPHI-UHFFFAOYSA-N heptadec-8-ene Chemical compound CCCCCCCCC=CCCCCCCC BIQKRILZMDQPHI-UHFFFAOYSA-N 0.000 description 1
- KYYWBEYKBLQSFW-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O KYYWBEYKBLQSFW-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- NLAGNNORBYGNAV-UHFFFAOYSA-N isotriacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCC(C)C NLAGNNORBYGNAV-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- QCAWEPFNJXQPAN-UHFFFAOYSA-N methoxyfenozide Chemical compound COC1=CC=CC(C(=O)NN(C(=O)C=2C=C(C)C=C(C)C=2)C(C)(C)C)=C1C QCAWEPFNJXQPAN-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229940038384 octadecane Drugs 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- SECPZKHBENQXJG-BQYQJAHWSA-N palmitelaidic acid Chemical compound CCCCCC\C=C\CCCCCCCC(O)=O SECPZKHBENQXJG-BQYQJAHWSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- NNNVXFKZMRGJPM-KHPPLWFESA-N sapienic acid Chemical compound CCCCCCCCC\C=C/CCCCC(O)=O NNNVXFKZMRGJPM-KHPPLWFESA-N 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention discloses a production method for extracting ant oil by supercritical CO2. The production method comprises the following steps: dry ants are pulverized into powder with the particle size of 40 to 80 meshes, continuous extraction is carried out at the temperature of 30 to 50 DEG C under the pressure of 25 to 35MPa for 1.5 to 2.5 hours by a supercritical CO2 extraction apparatus when the flow speed of CO2 is 18 kg/hr. The optimum condition comprises the following: the extraction temperature is 50 DEG C, the extraction pressure is 30Mpa, and the extraction time is 2 hours. Extracted ant oil is a red brown oily liquid with specific acid fragrance of ants at normal temperature, and the extracted ant oil has the advantages of good quality, low lead content, reservation of a certain amount of trace elements, such as zincum, manganese, etc., the reservation of natural aromatic ingredients and the bioactivity of volatile ingredients of ants, no environmental pollution, easy operation, etc. The present invention solves the problems that ant medicines and ant health foods, which are processed by the traditional method, has the long-standing disadvantages of high lead content, anaphylactic protein containing, poor mouth feel, large taken dosage, hypersensitivity and digestive tract reaction for some people, etc., and the ant oil has residual solvent when extracted by organic solvent.
Description
Technical field
The present invention relates to a kind of supercritical CO
2The production method of extraction ant oil.
Background technology
Ant is with a long history in China as food and medicine, and document " all gift heavenly officials " and " in the Book of Rites then " record is arranged the earliest: " sandbar fish or meat paste (sauce that ant egg is made) is presented food for the emperor." claiming that ant is to claim in profound coltfoal, the Qing Dynasty's Zhao Xuemin supplementary Amplifications of the Compendium of Materia Medica that the ant ovum is a ZHUANGYUANZI in Ming Dynasty's LI Shi-Zhen Compendium of Material Medica, nature and flavor are sweet flat, can beneficial strengths, damp color (beauty treatment), lactagogue juice is used for insufficiency of vital energy and blood after being ill, puerperal hypogalactia etc.Modern " Chinese medicine voluminous dictionary " (version in 1986, Shanghai science tech publishing house) included the record that Formica fusca is used as medicine.In some places of China, the custom that eats ant as the Yunnan the Dais remains always.External Mexican, African Ghanaian also have the custom of edible ant.
Formica fusca (polyrhachis) Polyrhachis vicina Roger is the medicinal and edible ant that is distributed widely in wide geographic area and Zhejiang Province on the south China the Changjiang river.Since the 1980s, Colleges Of Traditional Chinese Medicine Of Guangxi is old to be that [old be favour to favour, medicinal research-protein and the amino acid analysis of ant, the Guangxi Chinese materia medica, the 2nd phase of nineteen eighty-three], the Wang Zhong of Air Force Aviation Medical Inst. [Wang Zhong, Wang Zhenguo, Gu Shuncai, the composition analysis of big Formica fusca chloroform extract.Chinese materia medica research, 1997 the 3rd phases], Wu Zhicheng [Wu Zhicheng, ant and ant therapy, Shanghai scientific popularization press, 1994] etc. report, Formica fusca contains protein 42~67%, amino acid/11 is more than 8 kinds, 31 kinds of trace elements such as zinc, manganese, phosphorus, iron, calcium, aluminium, magnesium, VA, VD, VE, VB
1, VB
2, and VB
12Etc. VITAMIN, formic acid, glucide, lipid acid such as oleic acid, linolic acid; Have calmness, anti-inflammatory, relieving asthma, spasmolysis, anti-stress, ease pain, protect liver, enhancing and adjusting immunologic function, delay senility, kidney invigorating and YANG supporting, pharmacological action such as promoting blood circulation and removing blood stasis; This ant is applied to disease treatments such as rheumatoid arthritis, hepatitis B, diabetes and has unusual effect.In recent years, Beihua University is old to wait [Chen Jing, Song Wengang, Zhang Xiaogang quietly, the external tumor-inhibiting action research of polyrhachis, Beihua University's journal (natural science edition), 2000 the 5th phases] do to suppress the tumour test with the alcohol extract of this ant, discovery is to the toxic effect of mouse ascites sarcoma cell, to Mouse Liver oncocyte, mouse leukemia cell DNA are synthetic obvious restraining effect arranged; Old body interior inhibition test [Chen Jing, Guo Hong, Liu Muqing, the Zhu Jianqiang of waiting quietly, tumor-inhibiting action research in the polyrhachis body, Beihua University's journal (natural science edition), 2000 the 6th phases] show that alcohol extract has the growth of tumour cell of inhibition and prolongs the effect of tumor-bearing mice mean survival time.1992, this ant is classified new resource for food as through the health ministry approval, research and development through two more than ten years, Formica fusca has been widely used in Chinese patent medicine, hospital's Chinese medicine preparation, protective foods and new resource food production, the product that with the Formica fusca is development of raw materials production at present has the profound coltfoal oral liquid of Chinese medicine three kind new medicine compounds, profound seven capsule for treating arthralgia aggravated by cold, and other has immunomodulatory, the oral liquid of functions such as antifatigue, wine, electuary, powder, healthcare products such as capsule and teabag, not only quantity is many, market is big, also has good economic benefit [Shen Lirong, Ren Yucui, China's development and use edible and medical ant make progress.Insect knowledge, 1999 the 4th phases].In recent years, the ant health product have also spread to states such as Japan, the U.S..At Zhejiang Province's Formica fusca-Formica fusca, Zhejiang Province's Chinese medicinal materials standard is listed in Zhejiang Department of Public Health approval, Drug Administration of Shanxi Province's approval in, as hospital preparation with and the prescription medicinal material.
At present, China various places have been carried out medicinal, edible research, the Insecta of development and application, Hymenoptera, Formicidae, propagate artificially or wild edible and medical ant, comprise Formica fusca Polyrhachis vicinaRoger, two prominent thorniness ant Polyrhachis dives Smith, red chest thorniness ant Polyrhachis lamellidensSmith, blood red woods ant Formica sanguinea Latreiller, formica rufa Formica rufa Linnaeus, the hunchbacked ant Camponotus japonicus Mayr Oecophylla smaragdina Oecophylla smaradina ant species such as (Fabricius) of Japan.
Yet, present commercially available ant processed goods major part is with the capsule that the rough machined ant of traditional method does, Formica fusca powder is made, honeyed bolus, cream, Ants Wine etc., complete processing falls behind, product exists content of heavy metal lead too high, contain supersensitivity albumen, mouthfeel is poor, and dose is big, and part crowd has problems such as supersensitivity and digestive tract reaction.[Wang Zhong, Wang Zhenguo, Gu Shuncai, the composition analysis of big Formica fusca chloroform extract such as Wang Zhong in addition.Chinese materia medica research, 1997 the 3rd phases] the Ceng Youyong chloroform is as the report of organic solvent extraction ant volatile oil, but owing to there is organic solvent residual, harmful and to problems such as environment can pollute, common organic solvents extraction can only be as the method for extraction experiments analysis and specimen, and should not use as production method.Patent " Formica fusca extract and preparation thereof " (application number: 92105603.6, publication number CN 1067377A) introduced the method for producing preparations such as oral liquid with the ant ethanol extraction, do not relate to supercritical CO
2The production method of extraction ant oil and preparation thereof.
Summary of the invention
The purpose of this invention is to provide a kind of supercritical CO
2The production method of extraction ant oil.
The step of method is:
1) with Insecta, Hymenoptera, Formicidae, propagate artificially or wild edible and medical ant, comprise that the dry polypide of Formica fusca, two prominent thorniness ant, red chest thorniness ant, blood red woods ant, formica rufa, Japanese hunchbacked ant is processed into dry ant powder,
2) the ant powder is placed CO
2In the supercritical extraction device, CO
2After being condensed into liquid, ice chest enters high-pressure pump, the CO after the pressurization
2Entering the extractor in the extraction plant after the heater via heating, fully contact with wherein Formica fusca powder, is that 30~50 ℃, pressure are 8~40MPa, CO in temperature
2Flow velocity is under the condition of 10~18kg/hr, carries out continuous extraction in 1~3 hour, and top condition is CO
2Flow velocity is 18kg/hr, 50 ℃ of extraction temperature, extracting pressure 30Mpa, 2 hours extraction time.The fats compound that extracts is with CO
2Fluid enters separator, after fats compound is separated, and CO
2Enter ice chest again, obtain ant oil through cycling extraction repeatedly;
Described dry ant powder, its water content are pulverized the back and are used 10~15%, and granularity is 40~80 orders, as the raw material of supercritical extraction.
The used CO of supercritical extraction
2Purity 90~99%, in extracting operation, 90% ethanolic soln that adds 50% ant grain weight in extraction plant is as " entrainment agent ", during each extraction process 2.0 hours.
Ant oil passes through preliminary treatment, batching, mixing, is molded into soft capsule or dripping pill; Perhaps dry, be molded into micro-capsule.Ant oil accounts for 78.5% of weight percent in soft capsule or the dripping pill.
Ant is oily and pass through preliminary treatment, batching, mixing, be molded into soft capsule or dripping pill; Perhaps dry, be molded into micro-capsule.Ant oil accounts for 78.5% of weight percent in soft capsule or the dripping pill.The beta-cyclodextrin of micro-capsule or pure glue are 1: 4 (g/ml) with the ratio of ant oil.
The present invention adopts CO
2Supercritical process extraction ant oil, the ant that has overcome traditional method processing does, Formica fusca powder medicine, the ubiquitous content of heavy metal lead of protective foods are too high, contain supersensitivity albumen, mouthfeel is poor, dose is big, part crowd has supersensitivity and problem such as digestive tract reaction; Dissolvent residual problem when having solved organic solvent extraction, free from environmental pollution; The biological nature that has kept natural aromatic composition and the ant class volatile component of ant makes it become new raw material, the product innovation of nutritive health-care and medicine.
Embodiment
Embodiment 1:
Formica fusca is done impurity elimination, be dried to water content below 10%, being ground into granularity is 40 purpose powder.Use equipment to be the semicontinuous supercritical extraction unit of HL-1/32-50Mpa, mainly be made up of an extractor and three grades of separators, extractor and separator all have chuck, available hot water heating and constant temperature, extractor volume 1L.The extractor charging basket can be adorned 350g ant powder at every turn, and the 600-800 eye mesh screen is housed, and puts a steel wire lump earlier on the bucket end screen cloth, and after jar was gone into Formica fusca powder, a bucket upper port was put a steel wire lump again, and steel wire lump can play when machine moves and intercept the ant fine powder and the effect of blocking pipeline.Then the screen cloth lid is compressed into bucket, in the extractor of again charging basket being packed into.Used CO
2Purity should reach 90~99%.
Selected 3 extraction temperature levels (40 ℃, 45 ℃, 50 ℃), 3 extracting pressure levels (25,30,35Mpa), 3 extraction time horizons (1.5 hours, 2 hours, 2.5 hours), according to orthogonal design method by table L9 (3
3) arrange test, serve as to investigate index with the volatile oil yield, the level of factor arrangement sees Table 1, divides and operates for 9 times, takes statistics then and data analysis is compared, and draws optimum extraction condition.The unified CO that sets of each time operation
2Flow is 18kg/hr, and the separation reactor I temperature is that 45 ℃, pressure are 8Mpa, and separator II temperature is that 40 ℃, pressure are 6Mpa, and separator III temperature is that 33 ℃, pressure are 5Mpa.Each supercritical CO
2Extraction procedure: CO
2Steel cylinder → refrigeration system → high-pressure pump → extractor → separator I → separator II → separator III → refrigeration system (circulation).After each equipment operation, earlier extraction kettle → separator is carried out preheating, basin cools off, and when temperature reaches preset temperature, opens CO
2Gas cylinder is supplied gas, and opens high-pressure pump and boost, and when reaching predetermined pressure, the beginning cycling extraction is regulated CO
2Flow, constant temperature and pressure is collected volatile oil from separation reactor I after the extraction scheduled time.After the extraction scheduled time, with the CO of fats extract
2Fluid enters separator behind throttle expansion valve, in separator, because pressure reduces, temperature raises, and fluid density reduces, and is dissolved in CO in a large number
2Lipoid material in the fluid will be separated, and CO
2Fluid is got back to ice chest behind under meter, form circulation, carries out the extraction second time again, also can carry out the extraction more than three times by that analogy, most of extract enters separator I, can open separator I valve after each extraction is finished, and ant oil is collected in the plastic containers.
Orthogonal experiments is listed in table 2,9 groups the test in, the yield of ant oil be minimum be 11.43%, the highest
Table 1 Formica fusca supercritical extraction level of factor table
Level | Factor | ||
Temperature A (℃) | Pressure B (Mpa) | Time C (h) | |
1 2 3 | 40 45 50 | 25 30 35 | 1.5 2.0 2.5 |
Table 2 Formica fusca supercritical extraction orthogonal experiments
Test number | Factor | Volatile oil yield (%) | ||
A | B | C | ||
1 2 3 4 5 6 7 8 9 | 1 2 3 1 2 3 1 2 3 | 1 1 1 2 2 2 3 3 3 | 3 1 2 2 3 1 3 1 2 | 11.43 14.29 13.14 12.28 13.42 13.42 13.14 13.42 14.29 |
K 1 K 2 K 3 | 38.86 39.12 40.85 | 36.85 41.13 40.85 | 38.27 40.86 39.70 | |
k 1 k 2 k 3 | 12.95 13.04 13.62 | 12.28 13.70 13.61 | 12.75 13.62 13.23 | |
R | 1.99 | 4.28 | 0.87 |
Be 14.29%, normal temperature is the red-brown oily liquids down, and temperature is the peptone shape when being lower than 4 ℃, has fragrant smell, the free from extraneous odour grown of the distinctive acid of ant.K in the table 2
1, K
2, K
3Be the summation of respective horizontal gained volatile oil yield, k
1, k
2k
3Be respectively K
1, K
2, K
3Mean value, R is extreme difference, i.e. k
Max-K
MinAs seen from Table 2: (A) k
3>k
2>k
1, (B) k
2>k
3>k
1, (C) k
2>k
3>k
1, therefore, the best of breed extraction conditions of volatile oil is A
3B
2C
2, i.e. 50 ℃ of extraction temperature, extracting pressure 30Mpa, 2 hours extraction time; R value B>A>C promptly is arranged in order and is extracting pressure, extraction temperature, extraction time by the size that influences to the result.
Embodiment 2:
Operate according to the optimum extraction condition that embodiment 1 orthogonal experiments is drawn.Earlier Formica fusca is done impurity elimination, be dried to water content 10%, being ground into granularity is 80 purpose powder, use equipment to be the semicontinuous supercritical extraction unit of HL-1/32-50Mpa, this device mainly is made up of an extractor and three grades of separators, extractor and separator all have chuck, available hot water heating and constant temperature, extractor volume 1L.Getting purity ready is 90~99%CO
2350g ant powder is put into the extractor charging basket by embodiment 1 requirement, in the extractor of again charging basket being packed into.
From steel cylinder CO
2After ice chest is condensed into liquid, enter high-pressure pump, the CO after the pressurization
2Enter extractor after the heater via heating, fully contact with wherein Formica fusca powder, at CO
2Flow is 18kg/hr; Extraction temperature is that 50 ℃, extracting pressure are 30Mpa; Separator I temperature is that 45 ℃, pressure are 8Mpa, and separator II temperature is that 40 ℃, pressure are 6Mpa, and separator III temperature is that 33 ℃, pressure are under the condition of 5Mpa, extracts 2.0 hours, with the CO of fats extract
2Fluid enters separator behind throttle expansion valve, in separator, because pressure reduces, temperature raises, and fluid density reduces, and is dissolved in CO in a large number
2Lipoid material in the fluid will be separated, and CO
2Fluid is got back to ice chest behind under meter, form circulation, carries out the extraction second time again, also can carry out the extraction more than three times by that analogy, and the extraction time is 2.0 hours at every turn.Most of extract enters separator I, after finishing, extraction opens separator I valve, ant oil is collected in the plastic containers, get ant oil 52.5g, yield is 15.0% of an ant grain weight, and normal temperature is the red-brown oily liquids down, and temperature is the peptone shape when being lower than 4 ℃, have fragrant smell, the free from extraneous odour grown of the distinctive acid of ant.
The ant oil that supercritical extraction obtains adopts Agilent 6890N type chromatogram and 5973 type GC-MS (GC-MS) to detect, identify 51 compositions (seeing attached list 3), main component is followed successively by 9-18 carbon monoenoic acids [E] (45.10%), 9-alkene oleic acid-second fat (9.30%), cholesterol (6.00%), palmitinic acid (4.96%), 13,17-dimethyl hentriacontane (2.09%), 9-octyl group heptadecane (2.04%), ethyl palmitate (1.44%), 9-alkene oleic acid (1.41%), linolic acid (1.15%) etc.Wherein compositions such as 9-alkene oleic acid-second fat, cholesterol, palmitinic acid, ethyl palmitate, 9-alkene oleic acid, linolic acid do not appear in the newspapers in the past as yet in the ant
Its main component and with the ant oil base of extracted with diethyl ether this is consistent; But latter's gained composition kind is 37 (table 4), is less than the number of components of supercritical extraction ant oil.The CO that subordinate list 3 is measured for GC-MS
2The supercritical extraction ancient cooking vessel
The CO that table 3 GC-MS measures
2Supercritical extraction Formica fusca oil component
The composition sequence number | Peak Peak No | Retention value Retention Time (min) | Compound C ompound | Molecular formula Molecular formula | Relative content Relative Contents (%) | Degree of conformity Quality) |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 | 3 5 6 7 8 9 10 11 12 13 20 22 27 28 30 34 35 36 38 | 20.40 25.95 26.39 26.50 26.90 29.83 30.00 30.10 30.21 30.56 38.99 40.38 42.07 42.25 42.39 43.55 43.60 43.68 44.42 | 8-Heptadecane 8-17 alkene Hexadecenoic acid, Z-11 Z-11-16 carbon monoenoic acid n-Hexadecanoic acid palmitinic acid Ethyl 9-hexadecenoate 9-16 carbon monoenoic acid ethyl ester Hexadecanoic acid, Ethyl esert ethyl palmitate 9-Octadecenoic acid[E] 9-E-16 carbon monoenoic acids (alkene oleic acid) 9,12-Octadecadienoic acid[Z, Z] linolic acid (9,12,-Z, the Z-octadecadienoic acid) Ethyl oleate 9-alkene oleic acid-second fat Oleic acid 9-alkene oleic acid Octadecadienoic acid, Ethyl ester stearic acid second fat, Pentadecane, 8-hexyl 8-hexyl pentadecane Heptadecane, 3-methyl 3-methyl heptadecane 1-Hexacosen 1-cerotene 1-Octadecanethiol 1-nonadecane mercapto alcohol-10-Methylnonadecane 10-methyl nonadecane 9-Nonadecene 9-19 alkene-Nonacosanol triacontanol price quote 1-Docosene 1-docosene 17-(1,5-Dimethylhexyl)-10,13-dime1 | C 17H 34 C 16H 30O 2 C 16H 32O 2 C 18H 34O 2 C 18H 36O 2 C 18H 34O 2 C 18H 32O 2 C 20H 38O 2 C 18H 34O 2 C 20H 40O 2 C 21H 44 C 18H 38 C 26H 52 C 19H 39SH C 20H 42 C 19H 38 C 30H 62O C 22H 44 C 27H 46O | 0.12 0.44 4.96 0.78 1.44 45.10 1.15 9.30 1.41 0.43 0.58 0.17 0.53 0.24 0.33 0.28 0.37 0.51 6.00 | 87 98 99 98 95 99 87 99 96 96 90 91 89 97 80 92 83 91 93 |
20 21 22 23 24 other 27 compositions | 41 42 43 44 47 | 45.46 46.01 46.83 47.92 48.44 | -2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a] phenanthren-3-ol cholesterol Cholesta-3,5-diene 3,5-cholestadiene Nonadecane, 9-methyl 9-methyl nonadecane 1-Octadecanethiol 1-octadecane mercapto alcohol 13,17-Dimethylhentriacontane 13,17-dimethyl hentriacontane Heptadecane, 9-octyl-9-octyl group heptadecane straight chain high-carbon alkanes | C 29H 46 C 20H 42 C 18H 37SH C 33H 68 C 25H 52 | 1.04 0.41 0.23 2.09 2.04 16.33 | 97 90 91 93 86 |
Table 4 GC-MS measures the Formica fusca oil component of extracted with diethyl ether
The component list of prominent thorniness ant oil, subordinate list 4 are measured the component list of extracted with diethyl ether Formica fusca oil for GC-MS.
The composition sequence number | Peak Peak No | Retention value Retention Time (min) | Compound C ompound | Molecular formula Molecular formula | Relative content Relative Contents (%) | Degree of conformity Quality (%) |
1 2 3 4 5 6 7 8 9 10 11 | 2 5 7 8 9 10 11 20 21 24 25 | 10.52 20.41 25.89 26.29 29.83 30.00 30.09 41.73 42.25 43.55 43.60 | 2-Cyclohexen-1-ol 3-Hexadecene 3-hexadecylene 9-Hexadecenoic acid. 9-16 carbon monoenoic acid n-Hexadecanoic acid palmitic acid 9-Octadecenoic acid[E] 9-E-16 carbon monoenoic acids (alkene oleic acid) Octadecadienoic acid oleic acid Ethyl 9-octadecenoate 9-alkene oleic acid-second fat Heptadecane, 9-cctyl-9-octyl group heptadecane Cyclotriacontane ring melissane 1-Nonadecene 1-19 alkene-1-Docosene 1-docosene | C 6H 10O C 16H 33 C 16H 30O 2 C 16H 32O 2 C 18H 34O 2 C 18H 36O 2 C 20H 38O 2 C 25H 52 C 30H 60 C 19H 38 C 22H 45 | 0.33 0.41 0.30 3.30 35.70 2.63 0.91 3.74 0.24 0.44 0.56 | 53 90 42 96 99 70 58 93 90 89 91 |
12 13 14 15 16 17 18 other 19 compositions | 27 30 31 32 36 37 39 | 44.42 45.46 46.02 46.83 48.62 49.32 52.94 | 17-(1,5-Dimethylhexyl)--10,13-dimethy 3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a] phenanthren-3-ol cholesterol Cholesta-3,5-diene 3,5-cholestadiene Heptadecane, 2-methyl-2-methyl heptadecane Z-5-Nonadecene Z-5-19 alkene Pentadecane, 8-hexyl-Sitosterol acetate acetate Sitosterol ester 13,17-Dimethylhentriacontane 13,17-dimethyl hentriacontane straight chain high-carbon alkanes | C 27H 46O C 29H 48 C 18H 38 C 19H 38 C 21H 44 C 29H 52 C 33H 68 | 10.52 0.39 0.38 2.87 3.07 0.66 2.89 32.42 | 93 99 89 87 83 64 90 |
Adopting IRIS Intrepid II type to compose plasma emission spectrometer entirely measures, the ant oil that supercritical extraction obtains contains heavy metal and becomes plumbous 0.80 μ g/g, lead tolerance is lower than limiting the quantity of of national relevant food hygienic standard regulation, reduces more than 1 times than general Formica fusca powder (about leaded 2 μ g/g); Contain zinc 0.54 μ g/g, manganese 0.15 μ g/g simultaneously, promptly kept a certain amount of trace element.
Through the CO that uses of the present invention
2After overcritical Cui gets fats compound, the Formica fusca powder raw material can carry out extraction, the enzymolysis of other effective ingredient again with other method, and and then as the raw material of processing medicine, protective foods, the ant oil that obtains through extraction has kept the biological activity of natural aromatic composition and the ant class volatile component of ant, has quality better, cost is low,, do not contain advantages such as organic dissolvent residual.
Embodiment 3:
Formica fusca is done impurity elimination, be dried to and contain the Heshui amount 10%, being ground into granularity is 40 purpose powder.Use equipment to be the semicontinuous supercritical extraction unit of HL-1/32-50Mpa, getting purity ready is 90~99%CO
2350g ant powder is put into the extractor charging basket by embodiment 1 requirement, in the extractor of again charging basket being packed into.
From steel cylinder CO
2After ice chest is condensed into liquid, enter high-pressure pump, the CO after the pressurization
2Enter extractor after the heater via heating, fully contact with wherein Formica fusca powder, at CO
2Flow is 18kg/hr; Extraction temperature is that 50 ℃, extracting pressure are 30Mpa; Separator I temperature is that 45 ℃, pressure are 8Mpa, and separator II temperature is that 40 ℃, pressure are 6Mpa, and separator III temperature is that 33 ℃, pressure are under the condition of 5Mpa, extracts.After extraction process begins 0.5 hour, in device, add percentage concentration and be 90% ethanolic soln (for ant grain weight amount 50%) as " entrainment agent ".
CO with extract
2Fluid enters separator behind throttle expansion valve, in separator, because pressure reduces, temperature raises, and fluid density reduces, and is dissolved in CO in a large number
2Extract will be separated in the fluid, and CO
2Fluid is got back to ice chest behind under meter, form circulation, carries out the extraction second time again, also can carry out the extraction more than three times by that analogy, and the extraction time is 2.0 hours at every turn.
The ant oil of collecting is handled by distillation, ethanol is reclaimed.The ant oil that supercritical extraction obtains adopts Agilent 6890N type chromatogram and 5973 type GC-MS (GC-MS) combined instruments to detect ethanol and carries the ant oil of extraction secretly, identify palmitinic acid, oleic acid, cholesterol, 3,47 compositions such as 5-cholestadiene, clionasterol, linolic acid, stearic acid second fat (see attached list 5,), its main component and with the ant oil base of extracted with diethyl ether this is consistent, but latter's gained composition kind is 37 (seeing Table 4), is less than the one-tenth mark of supercritical extraction ant oil.Subordinate list 5 is with ethanol entrainment agent CO for GC-MS mensuration
2The component list of supercritical extraction Formica fusca oil, subordinate list 4 are measured the component list of extracted with diethyl ether Formica fusca oil for GC-MS.
The usefulness ethanol that table 5 GC-MS measures is as the CO of entrainment agent
2Supercritical extraction Formica fusca oil component
The composition sequence number | Peak Peak No | Retention value Retention Time (min) | Compound C ompound | Molecular formula Molecular formula | Relative content Relative Contents (%) | Degree of conformity Quality (%) |
1 2 3 4 5 6 7 8 9 10 11 | 4 6 7 8 9 10 12 13 18 25 26 | 20.41 25.97 26.43 26.90 29.86 30.12 30.56 32.33 38.19 40.81 40.89 | 3-Heptadecane 3-17 alkene Z-7-Hexadecenoic acid, Z-7-16 carbon monoenoic acid n-Hexadecanoic acid palmitinic acid Hexadecanoic acid, Ethyl esert ethyl palmitate 9-Octadecenoic acid, [E] 9-E-16 carbon monoenoic acids (alkene oleic acid) Ethyl oleate 9-alkene oleic acid-second fat 9-Octadecadienoic acid, (E) stearic acid Dodecane, 2,6,11-trimethyl 2,6,11-trimethyldodecane 17-Pentatriacontene 17-30 pentaene 1-Nonadecene 1-19 alkene 17-pentatriacontene 17-30 pentaenes | C 17H 34 C 16H 20O 2 C 16H 32O 2 C 18H 36O 2 C 18H 34O 2 C 20H 38O 2 C 18H 36O 2 C 15H 32 C 35H 70 C 19H 38 C 35H 70 | 0.21 0.91 9.54 0.37 51.53 6.55 0.14 0.24 0.28 0.11 0.14 | 99 96 99 99 83 83 94 60 90 92 76 |
12 13 14 15 16 17 18 19 20 21 22 other 25 compositions | 28 33 34 37 39 41 44 47 49 55 56 | 41.02 42.25 42.30 43.32 43.55 43.70 44.42 45.48 46.84 50.17 53.06 | 1-Docosanol tricosanol 13-Tertadecene-1-ol acetate 13-tetradecenoic acid ethyl ester 11-Metylnonacosane 11-methyl octacosane gamma,-sitosterol clionasterol 1-Nonadecene 1-19 alkene 17-Pentatriacontene 17-30 pentaene 17-(1,5-Dimethylhexyl)-10,13-dimetl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a] phenanthren-3-ol cholesterol Cholesta-3,5-diene 3,5-cholestadiene 1-Octadecene 1-octadecylene Octadecane, 9-ethyl-9-heptyl-9-ethyl, 9-heptyl octadecane A '-Neogammacer-22 (29)-en-ol, Acetate, (3.beta., 21.beta.) straight chain high-carbon alkanes | C 23H 46O C 16H 30O 2 C 29H 60 C 29H 50O C 19H 38 C 35H 70 - C 29H 46 C 18H 36 C 27H 58 C 32H 52O 2 | 0.18 0.17 0.14 0.70 0.28 0.60 4.96 1.09 0.24 0.32 2.35 14.12 | 89 70 43 99 98 81 92 99 64 38 46 |
Through the supercritical CO of using of the present invention
2After Cui gets fats compound, the Formica fusca powder raw material can carry out extraction, the enzymolysis of other effective ingredient again with other method, and and then as the raw material of processing medicine, protective foods, the ant oil that obtains through extraction has quality better, cost is low, does not contain advantages such as organic dissolvent residual.
Embodiment 4:
The preparation of ant oil soft capsule (or dropping pill formulation).(1) preparation of content: ant oil is added salad oil, and salad oil accounts for 22.5% of gross weight, and vitamin-E accounts for 0.5%.In temperature is that 40 ℃, pressure are homogeneous under the condition of 6MPa, promptly gets soft capsule content.(2) join glue: sizing material is made up of 55% gelatin, 20% glycerine and 25% water.At first G ﹠ W is added in the impregnation jar, feed steam-heated cal(l)andria to 70~80 ℃, the back that stirs slowly adds gelatin, wants vigorous stirring simultaneously in order to avoid the formation agglomerate.Will continue heating when gelatin adds, when impregnation jar core temperature reaches 90~100 ℃, be incubated 3 hours, it is standby that filtration is cooled to 65 ℃ of left and right sides.(3) prepare before the pill: sizing material is placed be incubated in the appropriate vessel at 60 ℃, it is stand-by in addition content to be put into canned groove.The water dropper temperature is about 50 ℃, and room temperature remains on 10~20 ℃, and 100,000 grades of purification conditions will be arranged.(4) pill: adopt the spinning block platen press, behind the unlatching machine, glue flows through on cylinder, forms certain thickness adhesive tape, enters between wedge shape injector and the cylinder through feeding roller again.Jar is gone into semi-enclosed capsule and pill on the mold filling tube, along with the relative rotation of mold filling cylinder, capsule closed moulding.
Embodiment 5:
The preparation of ant micro-capsule (inclusion compound): take by weighing (60 ℃ in beta-cyclodextrin or pure glue, 2 hours dryings) 20g, add the 400ml aquae destillata, heating for dissolving, slowly add 5ml ant oil, mixing, stirred 1 hour with ultrasonic 20 minutes of Ultrasonic Cleaners when ultrasonic (be controlled at 20 ℃ of water temperatures) or with electric mixer regularly, put refrigerator (4 ℃) then 24 hours, suction filtration is got filter residue, or centrifugal (2500 rev/mins, 10 minutes) taking precipitate, with petroleum ether filter residue or throw out, hung 24 hours, 40 ℃ of constant temperature dryings 4 hours get product.Powdered micro-capsule can be sub-packed in capsule and make capsule or be pressed into tablet.
Claims (4)
1. supercritical CO
2The production method of extraction ant oil, it is characterized in that: the step of method is:
1) with Insecta, Hymenoptera, Formicidae, propagate artificially or wild edible and medical ant, the dry polypide that comprises Formica fusca, two prominent thorniness ant, red chest thorniness ant, blood red woods ant, formica rufa, Japanese hunchbacked ant is processed into dry ant powder, the dry ant powder water content is 10~15%, and granularity is 40~80 orders;
2) dry ant powder is placed supercritical CO
2In the extractor, CO
2After being condensed into liquid, ice chest enters high-pressure pump, the CO after the pressurization
2Entering extractor after the heater via heating, fully contact with wherein Formica fusca powder, is that 30~50 ℃, pressure are 25~35MPa, CO in temperature
2Flow velocity is under the condition of 10~18kg/hr, carries out continuous extraction in 1.5~2.5 hours, and the fats compound that extracts is with CO
2Fluid enters separator, after fats compound is separated, and CO
2Enter ice chest again, obtain ant oil through cycling extraction repeatedly; Ant oil can be measured 51 volatile constituents with the GC-MS method, the used CO of supercritical extraction
2Purity 90~99%, in extracting operation, 90% ethanolic soln that adds 50% ant grain weight in extraction plant is as " entrainment agent ".
2. a kind of supercritical CO according to claim 1
2The production method of extraction ant oil is characterized in that: described ant oil passes through preliminary treatment, batching, mixing, is molded into soft capsule or dripping pill; Perhaps dry, be molded into micro-capsule.
3. a kind of supercritical CO according to claim 2
2The production method of extraction ant oil, it is characterized in that: ant oil accounts for 78.5% of weight percent in described soft capsule or the dripping pill.
4. a kind of supercritical CO according to claim 2
2The production method of extraction ant oil, it is characterized in that: described micro-capsule, beta-cyclodextrin or pure glue are 1: 4 (g/ml) with the ratio of ant oil.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410015825 CN1225528C (en) | 2004-01-12 | 2004-01-12 | Supercritical CO2 extraction process for preparing ant oil |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410015825 CN1225528C (en) | 2004-01-12 | 2004-01-12 | Supercritical CO2 extraction process for preparing ant oil |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1557924A CN1557924A (en) | 2004-12-29 |
CN1225528C true CN1225528C (en) | 2005-11-02 |
Family
ID=34351532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410015825 Expired - Fee Related CN1225528C (en) | 2004-01-12 | 2004-01-12 | Supercritical CO2 extraction process for preparing ant oil |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1225528C (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100463955C (en) * | 2006-01-26 | 2009-02-25 | 山西亚宝药业集团股份有限公司 | Extraction method of effective ingredients from ants |
CN100381128C (en) * | 2006-05-29 | 2008-04-16 | 南京中山制药有限公司 | Inclusion compound of ants supercritical extracts and preparation process thereof |
CN101649249B (en) * | 2009-09-07 | 2012-12-12 | 浙江大学 | Method for preparing ostrich oil |
CN101838585B (en) * | 2010-05-31 | 2012-03-28 | 天津强微特生物科技有限公司 | Method for extracting grease from artemia or artemia eggs |
CN103125989B (en) * | 2012-03-31 | 2014-08-06 | 大连工业大学 | Method of extracting fish cerebrol and fish brain peptide |
CN104663933A (en) * | 2015-02-17 | 2015-06-03 | 杭州艺福堂茶业有限公司 | Disposable tea processing technology |
CN106823451B (en) * | 2017-02-27 | 2020-12-18 | 山西省食品研究所(有限公司) | Increase of CO2Charging process for supercritical extraction yield |
CN106890258A (en) * | 2017-03-31 | 2017-06-27 | 锦州德铭微量元素技术有限公司 | A kind of natural organic trace element concentrate and its production method |
CN108125986A (en) * | 2017-12-24 | 2018-06-08 | 广西南宁秀珀生物科技有限公司 | The extracting method of effective ingredients from ants |
CN107930181B (en) * | 2017-12-24 | 2021-04-02 | 广西南宁秀珀生物科技有限公司 | Ant extraction process based on supercritical carbon dioxide extraction method |
CN108057259B (en) * | 2017-12-24 | 2021-04-02 | 广西南宁秀珀生物科技有限公司 | Method for extracting effective components from ants by supercritical carbon dioxide |
CN112674261A (en) * | 2021-01-04 | 2021-04-20 | 贵州金山蚂蚁保健品有限公司 | Method for reducing heavy metal content of polyrhachis vicina roger |
CN115501257A (en) * | 2022-10-28 | 2022-12-23 | 江西中科佰氏药业有限公司 | Black ant antibacterial oil containing black ant oil and preparation method thereof |
-
2004
- 2004-01-12 CN CN 200410015825 patent/CN1225528C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1557924A (en) | 2004-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1225528C (en) | Supercritical CO2 extraction process for preparing ant oil | |
CN102698081B (en) | Medicinal liquor with treatment effect and health-care function and preparation method thereof | |
CN108477612A (en) | A kind of dendrobium nobile nutritive powder and preparation method including dendrobium candidum purified extract | |
CN103417601B (en) | A kind of medical composition and its use with regulating blood lipid action | |
CN102526315A (en) | Preparation method of extracts of effective fractions of lychee seeds | |
CN105394749B (en) | A kind of Ricipe for health care food and preparation method and application containing astaxanthin | |
CN104274498A (en) | Efficient antineoplastic lucid ganoderma extract and preparation method thereof | |
CN102329715A (en) | Compound Rhodiola rosea wine and preparation method thereof | |
CN110279727A (en) | A kind of sea-buckthorn triterpenic acid extract and preparation method thereof | |
CN106912952A (en) | A kind of preparation method of pharmaceutical composition and its capsule preparations with hypolipemic function | |
CN101472600A (en) | Medicament composition for regulating blood sugar and blood fat as well as preparation method and application thereof | |
RU2409381C1 (en) | Pharmaceutical composition for blood sugar and fat control, its manufacturing and administration thereof | |
CN102614280A (en) | Chinese medicinal composition with blood fat reducing effect, and preparation method and application thereof | |
CN1258372C (en) | Chinese medicinal composition for treating intestine irritable syndrome and its preparing method | |
CN101810674B (en) | Chinese medicinal composition for enhancing immunity, and preparation method thereof | |
CN105748652B (en) | Serissa japonica capsule for treating gout and preparation method thereof | |
CN105079134B (en) | It is a kind of for treat flu Chinese materia medica preparation preparation process and its application | |
CN108159146B (en) | Traditional Chinese medicine composition for reducing blood fat and preparation method thereof | |
CN109316565A (en) | A kind of blood-fat reducing composition and its preparation method and application | |
CN115487260B (en) | Traditional Chinese medicine composition for treating hypercholesterolemia or atherosclerosis and application thereof | |
CN1640436A (en) | Chinese medicine composition for treating menstrual period syndrome | |
CN102580108A (en) | Novel oily liquid auxiliary material for soft capsules for reducing blood fat | |
CN106912904A (en) | A kind of preparation method of grifola frondosus full agonist and products thereof | |
Malarvizhi et al. | Adipogenesis in obesity is modulated by IP6 in peanuts through activation of the nuclear receptors (PPARs) | |
CN101549008A (en) | Application of high-pressure continous extracted cassia seed extract in preparing hypolipemic medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051102 Termination date: 20100212 |